- Home
- FBRX vs CCCC Comparison
FBRX vs CCCC Comparison
Compare FBRX & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- CCCC
- Stock Information
- Founded
- FBRX N/A
- CCCC 2015
- Country
- FBRX United States
- CCCC United States
- Employees
- FBRX N/A
- CCCC N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- CCCC Health Care
- Exchange
- FBRX Nasdaq
- CCCC Nasdaq
- Market Cap
- FBRX 154.5M
- CCCC 175.1M
- IPO Year
- FBRX N/A
- CCCC 2020
- Fundamental
- Price
- FBRX $11.96
- CCCC $3.38
- Analyst Decision
- FBRX Strong Buy
- CCCC Strong Buy
- Analyst Count
- FBRX 3
- CCCC 4
- Target Price
- FBRX $68.00
- CCCC $8.50
- AVG Volume (30 Days)
- FBRX 79.4K
- CCCC 1.3M
- Earning Date
- FBRX 11-13-2025
- CCCC 10-30-2025
- Dividend Yield
- FBRX N/A
- CCCC N/A
- EPS Growth
- FBRX N/A
- CCCC N/A
- EPS
- FBRX N/A
- CCCC N/A
- Revenue
- FBRX N/A
- CCCC $34,240,000.00
- Revenue This Year
- FBRX N/A
- CCCC N/A
- Revenue Next Year
- FBRX N/A
- CCCC N/A
- P/E Ratio
- FBRX N/A
- CCCC N/A
- Revenue Growth
- FBRX N/A
- CCCC 16.55
- 52 Week Low
- FBRX $4.11
- CCCC $1.09
- 52 Week High
- FBRX $28.68
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- FBRX 59.36
- CCCC 69.68
- Support Level
- FBRX $10.11
- CCCC $2.58
- Resistance Level
- FBRX $11.57
- CCCC $3.65
- Average True Range (ATR)
- FBRX 0.84
- CCCC 0.24
- MACD
- FBRX 0.09
- CCCC 0.07
- Stochastic Oscillator
- FBRX 78.22
- CCCC 79.55
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.